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Identifying and defining the esophagogastric junctional 
adenocarcinoma (EGJA) as an independent disease apart 
from gastric cancer (GC) and esophagus cancer (EG) it 
has always been a difficult issue entailing doubts about 
the appropriate therapeutic approach. In fact, the EGJA 
is not entirely comparable with GC and EG in terms of 
epidemiology, risk factors, etiology and pathophysiology.
The incidence of EGJA has showing an opposite trend 
compared to GC because the incidence of EGJA has been 
increasing in the recent years while the GC has been 
decreasing. Furthermore, the EGJA prognosis is worse 
than the GC. In fact, EGJA has a lower prevalence of 
early gastric adenocarcinoma (5.6% vs. 22.2%, P<0.001) 
and R0 (86% vs. 92.8%, P<0.001) and a higher frequency 
of lymph node metastasis (76.3% vs. 67.4%, P<0.003) 
compared to GC (1).
Leers et al. (2) showed that the presence of reflux 
symptoms and peritumoral intestinal metaplasia is greater 
in the distal esophagus adenocarcinoma than in EGJA, 
while the location and prevalence of lymph node metastases 
is similar.
The incidence of EGJA, since the mid-1970s, has 
increased in Western countries, mostly in the white man 
and in the United States (3.1 per 100.000) surpassing EC 
and EG (3).
Messager et al. (4) compared five different European 
countries, noting that EGJA and EG predominate in 
Europe except in Spain where the GC is prevalent.
Conversely, in Eastern countries there are a few reports 
by incidence of EGJA. There has been a small increase of 
EGJA in Japan (5) and in China (6-11) in the recent years.
Since the borderline tumor location of EGJA between 
esophagus and stomach (stratified squamous epithelium 
vs. gastric simple columnar epithelium), a clear definition 
and classification of the tumor was necessary to arrive to an 
optimal therapeutic strategy.
In 1996, Siewert at al. (7) have proposed a different 
classification and definition of the EGJA. The EGJA is a 
neoformation growing within 5 cm from anatomical cardia 
(distally or proximally), dividing into three subtypes:
 Type I: adenocarcinoma of distal esophagus with 
extension from 1 to 5 cm above the junction (which 
may infiltrate the esophagogastric junction).
 Type II: adenocarcinoma of the cardia or “junctional 
carcinoma” with extension from 1 cm above to 2 cm 
under the junction.
 Type III: subcardial gastric carcinoma with extension 
from 2 to 5 cm under the junction (which may 
infiltrate the esophagogastric junction).
Type I is often associated with Barrett dysplasia and a 
long history of gastro-esophageal reflux disease (GERD).
The incidence of GERD is higher in the United States 
and in Europe than in Asia and Southern China. Although, 
in recent years it has been an increase on the frequency of 
GERD in Asia (8). 
In 2007 Siewert et al. (9) showed that in 79.5% of Type I 
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EGJA an area of intestinal metaplasia (Barrett’s esophagus) 
was present, while it was not found in the type III. This is 
probably due to the higher degree of undifferentiation (G3/
G4 grading) of type III compared to the type I (54.4% vs. 
73.4%). Epidemiologically type II has been considered a 
middle group between type I and type III.
Over the years, a possible correlation between GERD 
and EGJA has been discussed. Many authors have 
highlighted that a long exposure of gastric acid can damage 
epithelium of the esophagus and of the esophagogastric 
junction resulting mutation in Barrett’s esophagus, 
dysplasia, and then finally in adenocarcinoma (10-12). Chak 
et al. (11) have shown a strong association between EGJA 
and GERD related to other risk factors like a positive family 
story, age (older), gender (male) and obesity. However, not 
all the three types of EGJA seem to have a correlation with 
GERD. In fact, there is a positive correlation with the type 
I and not with the type II and III (12).
Liu et al. (6) have showed a recent increase of type I and 
type III prevalence and a type II decrease in 5,053 patients 
during 1988–2012. In type I the prevalence of GERD 
oscillated from 41.3% to 57.1%.
In the literature, many authors have attempted to 
identify the risk factors most involved on this type of 
tumors. Multiple studies have shown a strong correlation 
between smoking (pack-years of smoking) and increased 
risk of EGJA. Moreover, the use of alcohol appears to have 
no correlation with EGJA. Other risk factors involved in 
the onset of the EGJA are obesity and high fat dietary (13).
The choice of a more appropriate therapeutic strategy 
requires a correct staging of the disease determined by 
TNM classification. This is possible by using CT scan, 
endoscopic ultrasound, MRI and PET.
Many studies have shown the importance of radical 
surgery (radical resection of the tumor and complete 
lymphadenectomy) for a long-term survival in this type 
of tumors. However, it remains yet discussed the most 
appropriate surgical approach.
The possible surgical approaches for the EGJA include 
transhiatal total or subtotal gastrectomy, abdominothoracic 
total esophagogastrectomy, distal esophagectomy with 
resection of the proximal stomach, total gastrectomy with 
transhiatal resection of distal esophagus, limited resection 
of the esophagogastric junction or Ivor-Lewis.
Vrouenraets et al. (14) have highlighted an advantage 
in terms of fewer complications and reduced hospital 
stay performing the transhiatal esophagectomy approach 
for cardia cancer and EGJA compared to transthoracic 
approach with a better 5-year survival rate.
Hulscher et al. (15) compared transhiatal esophagectomy 
with extended transthoracic esophagectomy in patients with 
adenocarcinoma of the mid-to-distal esophagus or cancer 
involving the gastric cardia and the distal esophagus at early 
stage. The transhiatal approach is associated to a lower 
morbidity, while the 5-year survival was slightly better in 
the extended transthoracic approach.
Many authors described a different surgical approach 
according to the classification of Siewert. For the type I no 
impressive differences were found in the long-term survival 
rate between the radical transmediastinal esophagectomy 
and the transthoracic esophagectomy with the resection 
of proximal stomach. For type II and III a transhiatal total 
gastrectomy was recommend with the resection of distal 
esophagus (16-18).
In the early carcinoma (with tumors limited to the mucosa 
and without lymph node metastases, T1N0) a limited 
resection of the esophagogastric junction (16) possibly 
associated to the distal esophagus with interposition of a 
pedicled jejunal was indicated (17). Whereas, many authors 
have shown that the subtotal gastrectomy is characterized 
by an increased post-operative complications rate, such as 
increased incidence of reflux oesophagitis and anastomotic 
stenosis, compared to a total gastrectomy (18,19). 
In the stage T3/T4 a neoadjuvant therapy was 
recommended (17).
Duan et al. (20) compared the application of the right 
transthoracic Ivor-Lewis to the left transthoracic and 
thoracoabdominal approach in Siewert type II, concluding 
that the Ivor-Lewis approach is a more effective approach 
concerning the margin free resection, the adequate 
lymphadenectomy and the long-term patient survival.
The intraoperative digestive tract reconstruction 
after total gastrectomy plays an important role to reduce 
post-operative complications. The classic Roux-en-Y 
reconstruction is considered the optimal choice. Xiao 
et al. (21) compared the Roux-en-Y reconstruction with the 
antrum-preserving double-tract reconstruction showing that 
the Roux-en-Y approach is characterized by an increased 
complications rate such as cholelithiasis, malnutrition, 
dumping syndrome and esophageal reflux. Furthermore, the 
antrum-preserving double-tract reconstruction by jejunal 
interposition offers less hospitalization and reduces the 
gastroesophageal reflux, the malabsorption syndrome and 
the dumping syndrome. Moreover, they recommended this 
approach for the Siewert type I and III.
For the reconstruction of digestive tract in limited 
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resection (subtotal gastrectomy) a gastric-esophageal 
anastomosis is normally performed, leading to a severe 
alkaline reflux and a low quality of life. The interposition 
of an isoperistaltic jejuan or colon segment can improve the 
quality of life (22).
The 5-year survival in EGJA is also related to an 
adequate lymphadenectomy. Lymph node involving is less 
common in the type I than in the type II and III. In the type 
I is more common the lymph node dissemination in the 
mediastinum (in the tracheal bifurcation and above). Type II 
and III are most affected by the lymph node dissemination 
in the lower mediastinum and in the area of coeliac trunk (8).
In a German review (23) a D2-lymphadenectomy 
extended to the lower mediastinum by a transhiatal 
approach is recommended in type II and III. For type 
I is recommended a lymphadenectomy of the lower 
mediastinum and a lymphadenectomy of the perigatric 
region. 
In the esophagus-predominant adenocarcinoma a lower 
mediastinal lymphadenectomy has a greater therapeutic 
index value. In the stomach-predominant adenocarcinoma 
the right and left cardia, the small curvature, along the left 
gastric artery and the subpancreatic lymphadenectomy 
has a greater therapeutic index value. In conclusion, the 
prophylactic distal stomach lymphadenectomy seems to 
offer an advantage in terms of survival (24).
Finally, Ito et al. (25) showed a lack of cervical lymph 
node invasion in EGJA and a higher incidence of 
mediastinal lymph node metastasis in the esophageal-
predominant cancer, resulting in a lower survival compared 
to a gastric-predominant cancer.
Liu et al. evaluated a sample of 5,053 patients with 
GERD and EGJA underwent surgical treatment during 
a period of 25 years (from 1988 to 2012) highlighting 
the changing of epidemiological characteristics and 
treatment approaches in recent years. The study is well 
written, presenting a large number of patients enrolled 
during 5 homogeneous periods of time. Thus, the study is 
statistically valid.
The strength of this study is that in different periods of 
time various aspects were analysed: the changing trend of 
EGJA subtypes (Siewert classification), the changing trend 
of the presence of GERD in EGJA, the change of trend of 
clinical-pathological features and the changing of trend of 
surgical treatment and post-operative complications.
However, the study retains a retrospective nature, carried 
out in a single centre of Western China. Only patients who 
underwent surgical treatment were enrolled while those 
patients with EGJA who did not have the surgical treatment 
were excluded.
In conclusion, the recent increase of 5-year survival 
rate in EGJA may be due to the new EGJA classification 
(considering the EGJA a different tumor from esophagus 
or GC) and to the new technologies and surgical 
techniques. In the future, the advent of newer diagnostic 
techniques, allowing an earlier diagnosis, and innovative 
surgical techniques associated to decreased post-operative 
complications will probably lead to an improvement 
of survival and quality of life of patients with EGJA. 
Furthermore, an effective screening with a primary 
prevention can reverse the trend in countries with increased 




Conflicts of Interest: The authors have no conflicts of interest 
to declare.
References
1. Liu K, Zang W, Chen X et al. Comparison on 
Clinicopathological Features and Prognosis Between 
Esophagogastric Junctional Adenocarcinoma (Siewert 
II/III Types) and Distal Gastric Adenocarcinoma: 
Retrospective Cohort Study, a Single Institution, High 
Volume Experience in China. Medicine (Baltimore) 
2015;94:e1386.
2. Leers JM, DeMeester SR, Chan N, et al. Clinical 
characteristics, biologic behavior, and survival after 
esophagectomy are similar for adenocarcinoma of the 
gastroesophageal junction and the distal esophagus. J 
Thorac Cardiovasc Surg 2009;138:594-602.
3. DeMeester SR. Adenocarcinoma of the Esophagus and 
Cardia: A review of the desease and its treatment. Ann 
Surg Oncol 2006;13:12-30 
4. Messager M, de Steur WO, van Sandick JW, et al. 
Variations among 5 european countries for curative 
treatment of resectable oesophageal and gastric cancer: 
A survey from EURECCA Upper GI Group (Europian 
Registration of Cancer CAre). Eur J Surg Oncol 
2016;42:116-22.
5. Hasegawa S, Yoshikawa T. Adenocarcinoma of the 
1458 Pastina et al. The EGJA cancer
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2017;9(6):1455-1458jtd.amegroups.com
esophagogastrici Juntion: incidence, characteristics, and 
treatment strategies. Gastric Cancer 2010;13:63-73.
6. Liu K, Yang K, Zhang W, et al. Changes of Esophagogastric 
Junctional Adenocarcinoma and Gastroesophageal Reflux 
Disease Among Surgical Patients During 1988–2012. A 
Single-institution, High-volume Experience in China. Ann 
Surg 2016;263:88-95.
7. Siewert JR, Stein HJ. Classification of adenocarcinoma of 
the oesophagogastric junction. Br J Surg 1998;85:1457-9.
8. Lim LG, Ho KY. Gastroesophgeal reflux desease at the 
turn of millennium. World J Gastroenterol 2003;9:2135-6.
9. Siewert JR, Feith M. Adenocarcinoma of the 
esophagogastric juntion: competition between Barret and 
gastric cancer. J Am Coll Surg 2007;205:S49-S53.
10. Goldblum JR. Barrett's esophagus and Barrett's-related 
dysplasia. Mod Pathol 2003;16:316-24.
11. Chak A, Lee T, Kinnard MF, et al. Familial aggregation of 
Barrett's oesophagus, oesophageal adenocarcinoma, and 
oesophagogastric junctional adenocarcinoma in Caucasian 
adults. Gut 2002;51:323-8.
12. Yang K, Hu JK. The thinking to the huge disease burden 
of gastric cancer in China and the increasing tendency 
of esophagogastric junctional adenocarcinoma. Transl 
Gastroenterol Hepatol 2016;1:32.
13. Buas MF, Vaughan TL. Epidemiology and risk factors 
for gastroesophageal junction tumors: under standing 
the rising incidence of this disease. Semin Radiat Oncol 
2013;23:3-9.
14. Vrouenraets BC, van Lanschot JJ. Extent of surgical 
resection for esophageal and gastroesophageal junction 
adenocarcinomas. Surg Oncol Clin N Am 2006;15:781-91.
15. Hulscher JBF, van Sandick JW, de Boer AG, et al. 
Extended transthoracic resection compared with limited 
transhiatal resection for adenocarcinoma of the esophagus. 
N Engl J Med 2002;347:1662-9.
16. Stein HJ, Feith JR, Siewert JR. Individulized surgical 
strategies for cancer of the esophagogastric junction. Ann 
Chir Gynaecol 2000;89:191-8.
17. Stein HJ, Feith JR, Siewert JR. Cancer of the 
esophagogastric juntion. Surg Oncol 2000;9:35-41.
18. Rüdiger Siewert J, Feith M, et al. Adenocarcinoma of 
the esophagogastric junction. Results of surgical therapy 
based on anatomical/topographic classification in 1,002 
consecutive patients. Ann Surg 2000;232:353-61.
19. An JY, Youn HG, Choi MG, et al. The difficult choice 
between total andproximal gastrectomy in proximal early 
gastric cancer. Am J Surg 2008;196:587-91.
20. Duan XF, Yue J, Tang P, et al. Lymph node dissection for 
Siewert II esophagogastric junction adenocarcinoma: A 
retrospective study of 3 surgical procedures. Medicine 
(Baltimore) 2017;96:e6120.
21. Xiao JW, Liu ZL, Ye PC, et al. Clinical comparison of 
antrum-preserving double tract reconstruction vs roux-
en-Y reconstruction after gastrectomy for Siewert types II 
and III adenocarcinoma of the esophagogastric junction. 
World J Gastroenterol 2015;21:9999-10007.
22. Siewert JR, Feith M, Stein HJ. Biologic and clinical 
variation of adenocarcinoma at the esophago-
gastric junction: relevance of a topographic-anatomic 
subclassification. J Surg Oncol 2005;90:139-46.
23. Mönig SP, Schröder W, Beckurts KT, et al. Classification, 
diagnosis and surgical treatment of carcinomas of the 
gastroesophageal junction. Hepatogastroenterology 
2001;48:1231-7.
24. Yamashita H, Seto Y, Sano T, et al. Results of a nation-
wide retrospective study of lymphadenectomy for 
esophagogastric junction carcinoma. Gastric Cancer 
2017;20:69-83.
25. Ito H, Inoue H, Odaka N, et al. Clinicopathological 
characteristics and optimal management for 
esophagogastric junctional cancer; a single center 
retrospective cohort study. J Exp Clin Cancer Res 
2013;32:2.
Cite this article as: Pastina M, Menna C, Andreetti C, 
Ibrahim M. The esophagogastric junctional adenocarcinoma 
an increasing disease. J Thorac Dis 2017;9(6):1455-1458. doi: 
10.21037/jtd.2017.05.70
